Mark Zipkin Freelance Public Relations Consultant

SEngine Precision Medicine demonstrates potential of PARIS® Test to find unexpected therapeutic options for treating cancer

The PARIS Test, a CLIA-certified drug sensitivity assay, uses patient-derived tumor organoids to screen an array of drugs and develop personalized treatment reports. Ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas, was identified as the optimal treatment for a patient with ovarian cancer.